Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP) Article

Ruiz-Patino, Alejandro, Arrieta, Oscar, Cardona, Andres F et al. (2020). Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP) . THORACIC CANCER, 11(2), 353-361. 10.1111/1759-7714.13272

Open Access Industry Collaboration International Collaboration

cited authors

  • Ruiz-Patino, Alejandro; Arrieta, Oscar; Cardona, Andres F; Martin, Claudio; Raez, Luis E; Zatarain-Barron, Zyanya L; Barron, Feliciano; Ricaurte, Luisa; Bravo-Garzon, Maria A; Mas, Luis; Corrales, Luis; Rojas, Leonardo; Lupinacci, Lorena; Perazzo, Florencia; Bas, Carlos; Carranza, Omar; Puparelli, Carmen; Rizzo, Manglio; Ruiz, Rossana; Rolfo, Christian; Archila, Pilar; Rodriguez, July; Sotelo, Carolina; Vargas, Carlos; Carranza, Hernan; Otero, Jorge; Pino, Luis E; Ortiz, Carlos; Laguado, Paola; Rosell, Rafael

sustainable development goals

authors

publication date

  • February 1, 2020

published in

keywords

  • Adult
  • DOCETAXEL
  • GROWTH
  • INHIBITORS
  • Life Sciences & Biomedicine
  • NIVOLUMAB
  • OPEN-LABEL
  • OUTCOMES
  • Oncology
  • PEMBROLIZUMAB
  • PHASE-3
  • Respiratory System
  • Science & Technology
  • antagonists & inhibitors
  • drug therapy
  • immunotherapy
  • lung neoplasms
  • neoplasms
  • programmed cell death 1 receptor

Digital Object Identifier (DOI)

publisher

  • WILEY

start page

  • 353

end page

  • 361

volume

  • 11

issue

  • 2